Alfuzosin
Alfuzosin is a competitive antagonist at the a1 adrenergic receptor, used for symptomatic relief in benign prostatic hypertrophy. Alfuzosin is optically active quinazolone derivative prepared by chemical synthesis. The racemate is used clinically. Alfuzosin is administered orally.
Primary Characteristics
It is of Synthetic origin and belongs to Furancarboxamide.
It belongs to Alpha-1 adrenergic antagonist pharmacological group on the basis of mechanism of action and also classified in Selective 5-HT3 Receptor Antagonist pharmacological group.
Molecular Weight: 425.9 · pKa: 8.13 · Solubility in Water: freely soluble · Solubility in Alcohol: sparingly soluble · Non-proprietary name: Alfuzosin.

Pharmacokinetics
Absorption: Alfuzosin has an oral bioavailability is 64%.
Distribution: Alfuzosin has a volume of distribution is 2.5 l/kg. plasma protein binding is 90%.
Elimination: it is metabolised via hepatic, plasma half-life is 3.5-5.5 hr, renal excretion is 11%.
Advertisement
Indications
Alfuzosin is primarily indicated in conditions like Benign prostatic hyperplasia.
Alfuzosin is also indicated for secondary conditions like Hypertension.
Contraindications
Alfuzosin is contraindicated in conditions like Hypotension, Hepatic insufficiency, Hypersensitivity.
Dosage
Alfuzosin's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 6.25 mg | 6.25 mg | Every 8h | PO | Maximum 10mg/day. |
| 10 mg | 10 mg | Every 24h | PO | 10 mg/day as a single dose of modified release preparation. Take after meal. |
| Paediatric Dosage (20kg) | ||||
| 0 – 0 | — | — | — | Not Recommended in this Age Group |
| Neonatal Dosage (3kg) | ||||
| 0 – 0 | — | — | nnot recommended in this age group | |
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Alfuzosin is known to cause more or less tolerable side effects which are usually transient. These include dizziness, Headache, Nausea, Postural hypotension, Skin rash, Syncope , Tachycardia, Vertigo, Vomiting .
Warnings / Precautions
Available Brands
Storage Conditions
Drug Classification
- 1.12.3.5 — Alpha-1 receptor antagonists